Physicians' Academy for Cardiovascular Education

PCSK9, the short track road from discovery as drug target towards the clinic

10' education - Aug. 27, 2016 - ESC 2016, Rome - Gilles Lambert, MD – Université de la Réunion, Sainte-Clotilde, France

This lecture was part of a CME accredited symposium: PCSK9 inhibition in clinical lipid management: A critical review of evidence and opportunities held at ESC 2016 in Rome

Video navigation menu

  • The discovery of PCSK9 - a brief overview 00:14
  • Cardiovascular benefits of PCSK9 loss of function mutations 02:55
  • The biology of PCSK9 04:12
  • The development of PCSK9 inhibitors 08:34
  • PCSK9 inhibitors also reduce Lp(a) by increasing its hepatic secretion 09:43
  • Conclusion 12:36

Educational information

Educational objectives of this symposium were to:

CME accreditation

This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).


Prof Gilles Lambert is Professor in Cell Biology and Biochemistry at the University of La Réunion Medical School (France) and a principal investigator at Inserm UMR1188 DéTROI.


Supported by unrestricted educational grants from Amgen, Pfizer, and Sanofi-Regeneron.

Also view lecture: A clinical perspective on PCSK9 inhibition: What do we know an what can we expect? , by Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston Also view lecture: Preparing for a novel era in CV prevention: Where do PCSK9 inhibitors fit in lipid management?, by prof John Kastelein, MD – AMC, Amsterdam, The Netherlands